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ABSTRACT _
Objective. Researchers have often stated that economic
evaluations of new drugs have rarely been used to in-
form healthcare decisions, despite the large volume of
published studies. In this paper, a new categorization
for economic evaluations of new drugs is proposed: in-
cidence-based and prevalence-based. This categoriza-
tion is designed to increase the likelihood that decision-
makers are given more complete and useable economic
information about new treatments.
Results. Incidence-based evaluations (such as cost-effec-
tiveness analysis) focus on the impact of a new treatment
on a health condition from onset until cure or death.
Prevalence-based evaluations focus on the impact of a
new treatment on a health condition during a I-year pe-
Healthcare costs in the United States continueto receive intense scrutiny as government and
corporate budgets are increasingly constrained. De-
cisions about the total amount to spend on health-
care and the allocation of these resources are made
by many different providers of medical care in a
healthcare system. These decision-makers are re-
sponsible for containing costs and insuring that
the resources available are used to provide more
and better healthcare. In the United States these
decision-makers include: healthcare policy-makers;
administrators of managed care organizations; ad-
ministrators of government healthcare programs
such as Medicaid, Medicare, and the Veterans Ad-
ministration; pharmacists; prescribing physicians;
health insurance administrators; and employers who
pay for much of their employees' health insurance
premiums. All of these groups have a need for in-
formation on the economic value of alternative
healthcare interventions if they are to make truly
informed decisions about how much to spend on
healthcare and how to spend that amount most ef-
ficiently.
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riod. An incidence-based evaluation may focus either on a
representative individual or on a specific disease cohort.
A prevalence-based evaluation generally focuses on a spe-
cific population. Incidence-based evaluations measure the
value of the new treatment compared to alternative treat-
ments for the same health conditions and compared to
commonly used treatments for other health conditions.
Prevalence-based evaluations measure the impact of in-
troducing the new treatment on annual healthcare bud-
gets and population health.
Conclusion. Both types of evaluation provide important
information when a new treatment is introduced to a
population.
Recently, in a paper presenting a methodological
approach for performing cost-effectiveness analyses
(CEAs), Russell et al. [1] stated that "CEA is rarely
used to inform decisions about health services in
the United States." Sloan and Conover [2] make a
similar statement: "Cost-benefit/cost-effectiveness
analyses are rarely used in benefits coverage deci-
sions." Davies et al. [3] noted the same lack of im-
pact of CEA in the results of a survey in Europe
that indicated that economic evaluation has had
a relatively low impact on healthcare policy or
healthcare decision-making despite the large vol-
ume of research studies that have been published.
These findings raise a question about the usefulness
of the product that the research community is deliv-
ering. Economic evaluations may not be useful be-
cause the information presented is not in a format
that is useable and/or understandable by non-econ-
omists. Or it may be that researchers are providing
data that answer questions from a perspective dif-
ferent from that of the decision-maker in terms of
the range of outcomes included, the time horizon
considered, and the population included.
Many published economic evaluations have as
their goal the estimation of a cost-effectiveness ra-
tio, computed as the incremental cost with the new
treatment compared to the current therapy, divided
by the incremental benefits with the new treatment
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for a typical patient. This cost-effectiveness ratio
can be compared to a generally accepted value (e.g.,
$50,000 per life-year gained) to determine whether
or not the new treatment for the specific disease is a
good value for the money. This type of value mea-
sure is also very useful if decision-makers are trying
to determine the best way to allocate healthcare
funds between alternative uses. Thus, if they have a
fixed healthcare budget and want to get the best
value from that budget, they should allocate the
funds to the uses that give the most return for each
dollar spent. That is, they should allocate funds
first to the uses with the lowest cost-effectiveness
ratios.
In addition to a measure of drug value, such as
that given by the cost-effectiveness ratio, decision-
makers need to know by how much their annual
budget is likely to increase or decrease in year 1, 2,
and so on, after its introduction, if the new drug is
added to the formulary. They also need to know
what annual health benefits are likely to be associ-
ated with this budget increase or decrease. The
need for this type of information has been stated
recently by Foundation Health Corporation (FHC)
in its 1996 guidelines for formulary submission
[4]. However, there are very few published eco-
nomic evaluations that give this type of informa-
tion, although it is clearly of great relevance for de-
cision-makers. In addition, this type of analysis is
not generally included in methodological guides to
economic evaluation such as Gold et al. [5].
In order to begin to fill this methodological gap,
this paper presents a new categorization for eco-
nomic evaluations for new drugs: incidence-based
and prevalence-based, and describes general guide-
lines for performing each type of evaluation. The
paper also illustrates, with examples, the value of
prevalence-based estimates for different types of
treatments. The routine completion by researchers
of both types of economic evaluation for new
drugs will insure that healthcare decision-makers
have access to economic data in a format that is
useful to them.
A New Categorization for Economic
Evaluations of New Drugs
In their landmark study entitled "The Incidence and
Economic Costs of Major Health Impairments," [6]
Hartunian et al. distinguished between two analytic
approaches for estimating the economic costs of ill-
ness. These are an incidence-based approach and a
prevalence-based approach. The incidence-based
approach estimates lifetime costs of health impair-
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ments that are incident (first occur) in the popula-
tion in a given year. For each incident case, the total
discounted costs attributable to that impairment
are estimated regardless of whether those costs oc-
cur during the incident year or in subsequent years.
Hartunian et al. used this approach to estimate the
costs of major illness or accidents in the United
States in 1975 [6]. By contrast, the prevalence-
based approach estimates the costs attributable to
all in the population with a specific health impair-
ment during a specified year, irrespective of how
long they have had the impairment. This approach
was used by Cooper and Rice to estimate the costs
of major illness in the United States in 1972 [7].
Although there is a long tradition of distinguish-
ing between incidence-based and prevalence-based
approaches for estimating total costs associated
with specific health conditions [6], this distinction
has not been applied to estimations of the impact
of new drugs on healthcare costs and health and
other outcomes. Table 1 summarizes the key at-
tributes of the incidence-based and prevalence-
based approaches when applied to economic evalu-
ation of new drugs. The incidence-based approach
estimates the impact of the new drug on expected
lifetime costs and health and other outcomes for a
disease cohort (all persons newly diagnosed with
the disease in a given year) or for a representative
person with the disease of interest. The prevalence-
based approach estimates the impact of the new
drug on healthcare budgets, population health, and
other outcomes for years 1,2, and so on, after the
introduction of the new treatment into a specific
population. Estimates using the incidence-based ap-
proach are useful to decision-makers for allocating
a fixed budget among alternative healthcare inter-
ventions. Estimates using the prevalence-based ap-
proach are useful for decision-makers for budget
planning and for understanding population health
impacts. Recently, the distinction between the inci-
dence-based and prevalence-based approaches for
economic evaluations of new drugs was made by
Mauskopf and Simpson [8] in a poster presenta-
tion entitled "The Costs and Benefits of Alterna-
tive Drug Treatment Regimens for HIV Patients,"
and the distinction is also made in the FHC guide-
lines [4].
Incidence-Based Approach
The incidence-based approach to economic evalua-
tion is the traditional approach used by most ana-
lysts. Examples of analyses that follow this approach
include cost consequence analysis, cost-effectiveness
analysis, cost-utility analysis, and cost benefit analy-
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Table I A new characterization of economic evaluations of new drugs
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Analysis approach Population studied
Incidence-based One-year incidencecohort
or representative
individual
Prevalence-based All people with disease in
I-year period
Time span Exampleoutcome measures
Diseaseduration Incremental lifetime costs
Incremental life-years
Cost per life-year gained
One year Annual changein healthcare costs
Annual changein mortality or
morbidity
Value to decision-makers
Budget allocation decisionsamong
different treatments
Budget planning
Reaching target health outcomes
sis [5]. In this approach, the impact of the new treat-
ment on healthcare costs and health and other out-
comes for the complete duration of the disease are
estimated. These estimates may then be used to com-
pute incremental cost-effectiveness or cost-utility ra-
tios, comparing the new treatment with current
treatments. Detailed descriptions of how to perform
incidence-based economic evaluations are presented
in several publications [1,5,9-11].
The outcomes generally included in these analy-
ses include the impact of the new treatment on: di-
rect healthcare service use and costs such as hospital
care, outpatient visits, home healthcare, and drugs;
direct nonhealthcare services such as transporta-
tion, medical devices, and paid caregiver time; in-
direct costs such as lost productivity; and health
outcomes such as mortality rates and changes in
functional status and quality of life. The outcomes
included in a particular analysis depend on the per-
spective chosen. Gold et al. [5] recommend that a so-
cietal perspective, including all the outcomes listed
above, should be used to compute a cost-effective-
ness ratio for the reference case. Alternatively, if a
health system or other perspective is taken, only a
subset of these outcomes would need to be included
in the analysis.
The recommended procedure in Gold et al. [5],
for the societal perspective, is to look at only the
impact of the new treatment on the outcomes asso-
ciated with the disease of interest. For example, if
people are prevented from dying prematurely be-
cause of a new treatment, the extra medical care
costs for other diseases that they now live long
enough to experience are not typically included in
the analysis. If a health system or other perspective
were taken, however, it might be appropriate to in-
clude these additional healthcare expenses.
The appropriate time horizon for these analyses
depends on the disease. For an acute disease, the
time horizon would be for as long as the complete
episode of the disease. This may be 5-10 days for
influenza or common bacterial infections, or it may
be between 14 days and 2 years for a disease like
zoster. For a chronic disease, the appropriate time
horizon is the patient's remaining lifetime. For dis-
eases lasting more than 1 year, future treatment
costs and benefits are discounted back to the ini-
tial year at a recommended rate of 3% [5].
Sources of data for incidence-based analyses in-
clude clinical trial data, observational databases,
and expert opinion. The impact of the new treat-
ment on clinical endpoints will generally be derived
from clinical trial data. The impact on healthcare
service use may also come from clinical trial data or
may be obtained using observational databases or
expert opinion. Data from clinical trials for long-
lasting acute illness and for chronic illness will not
generally extend for the complete time horizon.
They may need to be extrapolated to the full time
horizon using observational databases and expert
opinion. For example, if we are interested in a cost-
effectivenessanalysis for cholesterol-lowering drugs,
clinical trials may only last for a period of 1 year. If
the key outcome is the reduced risk of coronary
events or stroke, this will not occur until many years
into the future. Only if the clinical trial is an ex-
tended one (such as the Scandinavian Simvastatin
Survival Study [4S] [12]), will the trial data be able
to be used for direct estimates of the reduced risk of
these longer-term outcomes.
The focus of incidence-based economic evalua-
tions is generally the individual patient. The im-
pact of the new treatment on lifetime costs and
health benefits for a representative patient are esti-
mated. The impact of the new drug may be differ-
ent for different types of patients, either those with
different disease severity or those with different de-
mographic characteristics. It is important that inci-
dence-based approaches recognize the differences in
the value of new treatments for different popula-
tion subgroups, though this is not frequently at-
tempted. Published examples of analyses that esti-
mate the impact of a new treatment on different
subpopulations include: 1) estimates of the impact
of neonatal surfactant rescue treatment for respira-
tory distress syndrome subdivided according to size
of the premature infant [13,14]; and 2) estimates of
the impact of tissue-type plasminogen activator
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(t-PA) compared to streptokinase for treating post-
myocardial infarction patients subdivided according
to subsets of patients defined by age and location of
the myocardial infarction [15]. In both examples,
the cost-effectiveness of the new treatment was very
different for different patient subgroups.
Prevalence-Based Approach
The second approach to economic evaluation is the
prevalence-based approach, where the impact of
the new treatment on annual costs, annual health,
and other outcomes in the population of interest is
estimated. Impacts on annual costs, health, and
other outcomes should be estimated both for the
first year that the new treatment is used as well as
projected out for future time periods.
A broad range of outcomes should be included in
the analysis if the societal perspective is taken. For
example, the outcomes impacted by a new treatment
might include annual research and prevention costs,
annual treatment costs and productivity losses, and
annual deaths and nonfatal health events. There
might also be changes in disease incidence and prev-
alence attributable to the new treatment, changes in
the distribution of disease severity within the preva-
lent population, and even changes in the proportion
of people with the disease who access and receive
treatment. If a health system or other perspective is
taken, only the relevant subset of these outcomes
would need to be included in the analysis.
As with the incidence-based approach, the per-
spective of the analysis is important in determining
whether or not to include additional costs from un-
related diseases. Although it is recommended [5]
that estimates taking a societal perspective and us-
ing the incidence-based approach ignore addi-
tional costs from other diseases when a new treat-
ment reduces the risk of premature death from the
disease being treated, this might not be the appro-
priate standard for a prevalence-based approach
for either the societal or health system perspective.
The extra costs of treating additional survivors are
real costs to society and decision-makers. The costs
need to be included in the analysis for the analysis
to be useful for their decision-making. These extra
costs can be determined by estimating the increased
size of the prevalent population as a result of the
life saving treatment and estimating the total ex-
pected healthcare costs for these people. For exam-
ple, drug prophylaxis for preventing pneumocystis
carinii pneumonia (PCP) infection in persons with
AIDS reduces the risk of death from PCP and thus
increases overall life expectancy for persons with
AIDS. If the number of newly diagnosed patients
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with AIDS stays constant, the size of the AIDS pop-
ulation alive at any time in a healthcare plan will in-
crease as each patient lives for a longer time period
after diagnosis. The additional healthcare costs be-
cause of the longer life expectancy should be in-
cluded in prevalence-based economic evaluations
whatever the perspective.
When looking at the impact of a new treatment
from the prevalence perspective, additional data
are needed beyond those needed for the incidence-
based approach including estimates of the size,
distribution of disease severity, and demographic
characteristics of the population of interest. Epide-
miology studies of the disease of interest will gen-
erally provide these data at the societal level. For
example, natural history data for the disease (e.g.,
sex-, race-, and age-specific incidence rates, life ex-
pectancy with the disease, and typical disease course)
can be used to categorize the prevalent population in
terms of number of people at each levelof disease se-
verity. These data can be used in combination with
the results of the incidence-based analyses to com-
pute estimates of the annual budget and health im-
pacts of the new treatment. For example, preva-
lence-based cost and health outcomes estimates for a
short acute nonfatal illness will equal the incidence-
based cost and health outcomes estimates times the
number of cases in the population of interest. This
relationship will be more complex for acute illness
with a nonzero fatality rate (i.e., acute illness that
may last for an extended period of time) or for
chronic illnesses.
Populations are likely to include people with a
mix of ages, sexes, and disease severity. This com-
plexity must be addressed explicitly for the preva-
lence-based approach to estimate the impact of the
new treatment on the specified population. Fre-
quently, the data available are sufficient only to
estimate the impact of new treatments on one or
two population subgroups. In this case, extrapola-
tion from these subgroups to other subgroups in
the population of interest will be required, using
observational databases or expert opinion.
The Value of the Prevalence-Based Approach
Estimates of the effect of a new drug on cost,
health, and other outcomes can be generated using
a prevalence-based approach and either a societal,
health system, or other perspective. These estimates
would be very valuable in giving policy-makers an
understanding of the likely impact of a new drug
on the annual burden of the disease for the econ-
omy or for their covered population. These esti-
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mates would allow the healthcare decision-maker
to evaluate the health benefits expected in the pop-
ulation for which they are responsible, as well as to
insure that their budgets are sufficient to allow
them to add the new drug.
Frequently, retrospective studies have demon-
strated the impact of new drugs on population
healthcare costs and population health. For exam-
ple, a study of surfactant therapy for neonatal res-
piratory distress syndrome showed that, after its
introduction, both mortality rates and hospital
costs for premature infants declined [16]. Another
study of an antidepressant drug showed that the
increased acquisition costs for the new drug were
completely offset by savings in other healthcare
costs for the depressed population [17]. These
studies, however, were not undertaken until the
drug had been in use for several years. Examples
are presented below of acute, chronic, and preven-
tive treatments for which prevalence-based analy-
ses at the time of new drug approval would pro-
vide useful information for healthcare decision-
makers.
Community Acquired Pneumonia
Community acquired pneumonia is a good exam-
ple of an acute illness for which both incidence-
and prevalence-based estimates have been computed
[18,19]. These two studies demonstrated similar effi-
cacy (cure rates) for alternative times to switch from
IV to oral antibiotic therapy and lower healthcare
costs for those patients switched to oral treatment
more rapidly. Individual patient estimates of health-
care cost savings (incidence-based estimates) are
easily converted into estimates for a population of
patients (prevalence-based estimates) by multiply-
ing them by the total number of patients in the
population. In this way, estimates can be obtained
of the possible savings from early switching to oral
therapy for a covered population. If the benefits of
early switching vary according to the bacterial
cause of the pneumonia and the extent to which the
bacteria are drug resistant, prevalence estimates
would take into account the relative prevalence of
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the different bacteria in the population of interest
to convert incidence-based estimates into popula-
tion estimates. In this way, a decision-maker can
determine the impact of earlier switching to oral
therapy for their own population.
Human Immunodeficiency Virus Infection
Another chronic illness, for which both incidence-
and prevalence-based estimates are needed, is HIV
infection. HIV is now a chronic disease whose suf-
ferers experience episodes of acute illness alternating
with periods of relatively healthy life. There are sev-
eral published estimates of cost-effectiveness for new
therapies estimated using incidence-based Markov
models [20-25]. These estimates present the incre-
mental lifetime costs per life-year saved for new
HIV treatments using health event data from clini-
cal trials combined with data from standard treat-
ment algorithms based on observational data and
expert opinion. Most of these estimates indicate
that new treatments for HIV are cost-effective rela-
tive to treatments for other diseases (see Table 2).
For example, because of its favorable cost-effective-
ness ratio, triple combination antiretroviral therapy
is the standard of care in the United States [23]. In
contrast, ganciclovir prophylaxis for cytomegalovi-
rus disease in persons with AIDS, which has a
much more unfavorable cost-effectiveness ratio, is
not standard therapy [26].
The impact of a new drug for HIV infection can
be estimated as its incremental cost per life-year
gained (an incidence-based estimate) or as its im-
pact on the annual budget and patient outcomes (a
prevalence-based estimate). While the incidence-
based estimates are constant over time, prevalence-
based cost and health outcomes will change over
time after the introduction of a new treatment, be-
ing different in year 1, 2 and so on, until a new
steady state is reached. This variability over time is
due to changes in the population size and CD4 cell
count distribution each year after introduction of
the new drug and depends on the magnitude of the
effect of the new drug on life expectancy. For exam-
ple, combination antiretroviral therapy, by increas-
Table 2 Cost-effectiveness ratios for antiretroviral treatment for HIVinfection
CD'! cell count
200-500
200-500
200-500
200-500
<200
3TC. Jamivudine; ZOV. zidovudine.
Intervention
ZDV vs ZDV+3TC [24]
ZDV vs ZDV+3TC+indivinavir [23]
ZDV+ 3TC vs indinavir [3 I]
ZDV+3TC vs ZDV+3TC+indinavir [31]
ZDV vs no antiretroviral treatment [32]
Cost per life-yeargained
$12.600
$10.000-$18.000
<$10.000
$30.000
$34.600
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ing life expectancy in the HIV-positive population,
will lead to higher prevalence of disease but at a
CD4 cell count distribution shifted towards higher
cell counts (i.e., less severe disease). Information
on the impacts for each year after the new therapy
is introduced is critical for decision-makers who
have to manage healthcare budgets.
There have been only two conference presenta-
tions on the impact of alternative HIV treatment
patterns on annual healthcare budgets and health
outcomes [8,27]. In these studies annual outpatient
drug costs and total health system costs and health
outcomes were estimated based on the CD4 cell
count distribution of the population, incidence
rates of opportunistic diseases at different CD4 cell
counts, and treatment decisions. Table 3 presents
the results of the Mauskopf and Simpson study [8].
Table 3 presents the budget and health impacts of
going from a treatment regimen that includes only
monotherapy with antiretrovirals and treatment, as
needed, of opportunistic diseases to a more com-
prehensive treatment regimen that includes prophy-
laxis for PCP and mycobacterium avium complex
(MAC), and chronic suppression for genital herpes.
Estimates of the impacts of new therapies on an-
nual healthcare budgets are critical for planning by
healthcare decision-makers in charge of AIDS drug
assistance programs (ADAPs) or Medicaid pro-
grams. The Mauskopf and Simpson model [8] was
used in 1994 by the North Carolina AIDS Drug As-
sistance Program (ADAP) to estimate the amount
of additional funding needed to move from a for-
mulary providing only antiretroviral monotherapy
to one providing prophylaxis and treatment for op-
portunistic infections as well. The model was also
used by the North Carolina ADAP to show the
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value of the more comprehensive formulary in
terms of the health benefits to the ADAP enrollees
and offsetting cost savings in other parts of the
health system.
A budget model, derived from the Mauskopf
and Simpson model [8], was designed to help
ADAP administrators when combination antiret-
roviral therapy became the US standard. In this
model, the impact of triple combination therapy
on annual costs and patient outcomes is assumed
to depend on: 1) the starting CD4 cell count distri-
bution within the population of interest; 2) when
in the disease progression the combination treat-
ment is given; and 3) its efficacy, measured as an
increase in CD4 cell count. The results from this
model are currently being used by ADAP adminis-
trators to support their requests to federal and
state governments for additional funds to pay for
the new protease inhibitors, as well as to help them
make decisions about how to allocate the new
treatments among their program participants [27].
Hepatitis B Vaccine
The third treatment example that illustrates the
value to a decision-maker of prevalence-based esti-
mates is the hepatitis B vaccine. The majority of
the costs associated with hepatitis B occur many
years after the initial acute episode. These costs
arise in a subset of those with acute disease who go
on to have chronic disease and a subset of these who
end up with either liver cancer or cirrhosis after a
time period of approximately 20 years. Vaccination
stops acute episodes immediately, but much of the
cost savings associated with a vaccine program will
be experienced only many years after the start of
the program, when the number of cases of liver
Table 3 Formulary comparisons: annual casesof opportunistic diseases (ODs) and healthcare costs per 100HIV-positive persons
Antiretrovirals and Antiretrovirals and
Antiretrovirals and prophylaxis for prophylaxis for
no prophylaxis PCP and HSV PCP, MAC, HSV
Opportunistic diseases (no. cases)
PCP 6.86 4.08 4.08
MAC 1.89 4.66 1.54
Other 13.70 19.29 19.29
Total 22.45 28.03 24.91
Genital herpes (HSV)
Episodes 92 58.8* 58.8*
Costs
Outpatient durgs $361,469 $417,276 $459,471
Total outpatient $434,781 $527,011 $565,339
Total inpatient $180,908 $211,420 $199,627
Total medical treatment costs $615,690 $738,430 $764,962
*Assuming only 33% of HSV positive population on chronic suppression.
HSV, herpes simplex virus; MAC, mycobacterium avium complex; PCP, pneumocystis carinii pneumonia.
Prevalence-Based Economic Evaluation
cancer or cirrhosis declines. Most estimates of the
cost-effectiveness of a vaccine program have taken
an incidence-based perspective and estimated the
incremental costs for the vaccine per case of hepa-
titis avoided or per life-year gained [28]. Costs sav-
ings in the future are discounted back to the cur-
rent time period. These estimates are helpful in
understanding the value of introducing hepatitis B
vaccine for different population subgroups.
Incidence-based estimates are less helpful to
budget holders in understanding how much money
they will have to spend on hepatitis B each year
over, for example, the next 20 years. Table 4 illus-
trates the costs and benefits over time from the
start of the vaccine program. In the first year of a
vaccine program, the budget will have to cover the
program's cost, as well as the costs of treating
chronic and end-stage hepatitis B from those who
acquired the disease before the vaccine was avail-
able. The cost of the vaccine program in the first
year is also larger than in subsequent years because
of start-up costs and the cost of vaccinating all of
those who would have been eligible in previous
years had the vaccine been available. The only off-
setting cost saving the first year will be from re-
duced expenditures for acute initial episodes of
hepatitis B. Thus, total expenditures on the vaccine
and disease treatment are likely to be much higher
the first year of the program than either before the
vaccine was available or in subsequent years. The
vaccine program costs will fall to a steady state
level sometime after the first year, once all catch-up
vaccinations are complete. Annual expenditures
for hepatitis B treatment will gradually fall after
the first year, as there are fewer cases of chronic
hepatitis requiring treatment as well as fewer acute
episodes. Hepatitis B expenditures, however, will
not start the decline to their final very low levels
until 10-20 years after the introduction of the vac-
cine, at which point the incidences of end-stage
hepatitis B, cirrhosis and liver cancer, begin to de-
cline. A study by Hamilton [29] shows the annual
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costs after starting a hepatitis B vaccination pro-
gram in a teaching hospital. He estimates the costs
and benefits of the vaccination program over the
first 10 years of implementation. He shows that
costs are initially high; they break even after 7 years;
and there are cost savings after 10 years.
Prevalence-based impacts of vaccination for
chicken pox are simpler to estimate, because chicken
pox is primarily an acute illness. In the Lieu et al.
study of chicken pox vaccination [30], they present
annual estimates of the costs and benefits of a vac-
cine program averaged over the first 10 years of the
program. This analysis was used as one input into
the Centers for Disease Control decision to recom-
mend this vaccination for all children.
Discussion
The lack of widespread use of the documented re-
sults of economic evaluations for new interventions
by US and European decision-makers is not surpris-
ing. Prevalence-based and incidence-based estimates
of economic outcomes from societal and health sys-
tem and other perspectives are necessary for a com-
prehensive view of the value of a new treatment
and for the economic evaluation to be of maximum
use to healthcare decision-makers. An incidence-
based cost-consequence estimate from the patient
perspective is useful for an individual physician and!
or patient as they choose between alternative treat-
ments for a specific condition. Also, incremental
cost-effectiveness ratios for a new treatment for dif-
ferent patient subpopulations, from a societal or
health system perspective, are critical measures of
the value of the new treatment, which can be used
by decision-makers responsible for allocating health-
care budgets across all types of healthcare interven-
tions. The cost-effectiveness ratio can be compared
with the values for other currently used therapies.
Healthcare decision-makers managing the health
and healthcare budgets for defined populations,
however, have critical additional information needs
Table 4 Hepatitis B vaccine program costs and benefits over time*
Year I Year 2 (year 3, etc.) Year 20
Disease treatment costs
Vaccine program costs
Total annual costs
Totalannualbeneflts
No acute
Chronic (-I to -18)
Cirrhosis and cancer (- 19)
Catch-up costs
New cohort
No acute
Chronic (-I to -17)
Cirrhosis and cancer (- 18)
New cohort
No acute
No chronic
No cirrhosis and cancer
New cohort
*Assuming the vaccine is completely effective, all vaccine catch-up costs occur during the first year, cirrhosis and cancer occur after 20 years with chronic disease.
258
from the health system perspective about how the
new drug is going to change their annual budgets
and the annual health and other outcomes for their
populations.
Despite the seeming value of prevalence-based
estimates to decision-makers, the majority of the
published economic evaluations take an incidence-
based approach. There are several possible reasons
for this. First, prevalence-based estimates are pop-
ulation-specific, depending on the size and case-
mix of the population. This increases the data
needs and the complexity of performing the analy-
ses. Second, there is a tradition of performing preva-
lence-based analyses retrospectively (by using large
databases) rather than at the time the new drug is
first introduced. Third, since most new drugs im-
prove health and increase total healthcare costs,
there may be a reluctance on the part of the drug
manufacturers to quantify this increase prospec-
tively. For example, prevalence-based estimates
found in the literature are often performed for pro-
grams where the government has a large stake, or
where they are funded by the government [30].
The fear that analyses showing increased health-
care costs with a new drug would be detrimental to
the sales of the new drug may not be accurate.
Decision-makers are willing to pay more for im-
proved health, as recent changes in HIV treatments
have shown. However, in these circumstances, de-
cision-makers can really benefit from estimates of
the budget impacts for planning purposes. The Ca-
nadian guidelines for cost-effectiveness analyses and
the FHC formulary submission guidelines both re-
quest this sort of information for healthcare costs,
but not for health benefits. It seems a more bal-
anced approach for analysts to take a prevalence-
based approach to economic evaluation, where an-
nual costs, population health, and other outcomes
are presented together.
Incidence-based estimates are useful for deter-
mining the overall value of the new treatment. If
efficiency is our goal, we would want to construct
a healthcare system in which we allocate all avail-
able funds to different uses based on cost-effec-
tiveness of the treatment [2]. If a new drug reduces
overall costs, then we would always want to add
that drug to the formulary. However, in this type
of healthcare system, every time a new drug comes
along that increases overall costs but is more cost-
effective than at least one existing treatment, some
older, less cost-effective treatment-perhaps one
designed for a different condition-e-could no longer
be used if total costs are to remain unchanged.
This is a difficult type of system to implement on a
Mauskopf
day-to-day basis. It is more likely that healthcare
budgets will continue to increase as new drugs that
increase health at an acceptable cost continue to be-
come available. If this is the case, it is important
that researchers performing economic evaluations
for new products provide estimates to decision-
makers of these budget increases, the associated
health benefits, and the timing of these changes af-
ter introduction of the new drug, so that decision-
makers can justify additional budget requests or
make plans to lower other costs.
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